Home > Insider Trading > Filing (0001209191-15-007132)

Filing Details

Accession Number:: 0001209191-15-007132
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-01-28 17:56:52
Reporting Period:: 2015-01-26

Filing Date:: 2015-01-28
Accepted Time:: 2015-01-28 17:56:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1423824	Alder Biopharmaceuticals Inc	ALDR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1604834	James Mark Litton	11804 North Creek Parkway South Bothell WA 98011	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-01-26	5,200	$28.03	84,159	No	4	S	Direct
Common Stock	Disposition	2015-01-27	2,300	$28.52	81,859	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2015-01-26	35,000	$0.00	35,000	$28.23

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,000		2025-01-25	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	30,000	Indirect	Held in trust for the benefit of Reporting Person's minor child
Common Stock	30,000	Indirect	Held in trust for the benefit of Reporting Person's minor child
Common Stock	30,000	Indirect	Held in trust for the benefit of Reporting Person's minor child

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $28.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
Includes 875 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 28, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $29.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of the vesting commencement date and 1/48th of the total number of shares each monthly anniversary of the vesting commencement date thereafter, for so long as the recipient of the option provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.